Leptin Signaling in Lean and Obese Humans
Withdrawn
- Conditions
- Obesity
- Registration Number
- NCT01297426
- Lead Sponsor
- VA Office of Research and Development
- Brief Summary
Obesity does not respond to high circulating levels of the hormone leptin. This study is aiming at finding out why this happens and open new avenues for treatment of obesity.
- Detailed Description
Ex vivo and in vitro identification and study of leptin signaling pathways in commercially available cell lines serum/ plasma samples and discarded tissues from humans.
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- men and women
- ages 18 to 65
- BMI ranges between 20 and 45 kg/m2
Read More
Exclusion Criteria
- subjects requiring special diets
- history of illness other than obesity of diabetes
- taking medications known to influence glucose metabolism
- subjects with history of anaphylactic reaction or hypersensitivity to e. coli derived proteins or anesthetic agents
- women who are breastfeeding, pregnant or wanting to become pregnant
- subjects with bleeding dyscrasia or poor wound healing
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Westerns / activation of signaling pathways (uo to two hours after treatment) 04/01/2016
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
🇺🇸Boston, Massachusetts, United States